Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Combined With NKG2D CAR-NK Cell Therapy for Reducing the HIV Viral Reservoir
NCT07577986Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat, NKG2D CAR NK cells in human immunodeficiency virus infection (HIV), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Planned start May 2026; status: not yet recruiting.
02
Drugs
tucidinostatNKG2D CAR NK cells
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07577986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07577986.